Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 52 of 6351
-
Can adding pyrotinib shrink HER2-Positive breast tumors before surgery?
Disease control Recruiting nowThis is a randomized, open-label, superiority, multicenter clinical trial for patients with early or locally advanced (T≥2cm, N0-3, M0) HER2-positive breast cancer. It aims to compare the efficacy of neoadjuvant treatment with 2 cycles of Pyrotinib + Trastuzumab + Docetaxel follo…
Phase 3 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Lab-Grown tumor clusters guide tailored bladder cancer therapy
Disease control Not yet recruitingThis study evaluates Patient-derived Tumor-like Cell Clusters (PTC)-guided individualized neoadjuvant therapy in patients with muscle-invasive bladder cancer who are candidates for radical cystectomy.
Phase 2 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug cocktail aims to outsmart untreatable bile duct cancer
Disease control Not yet recruitingThis is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of arterially directed therapy in combination with tislelizumab plus lenvatinib compared with gemcitabine and cisplatin (GEMCIS) in combination with tislelizumab…
Phase 3 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New Four-Drug cocktail aims to wipe out Hard-to-Treat myeloma
Disease control Not yet recruitingThe goal of this study is to evaluate treatment of newly diagnosed multiple myeloma patients with t(11;14) suitable for transplantation using the SonKRd regimen, consisting of Sodium Thiotepa, Caffizotide, Lenalidomide, and Dexamethasone. Main objectives is to evaluate the MRD ne…
Phase 4 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Can a One-Time brain surgery free children from a lifetime of shunts?
Disease control Not yet recruitingHydrocephalus remains one of the most common conditions encountered in neurosurgery, traditionally managed by ventriculoperitoneal (VP) shunting. Despite its effectiveness, shunt dependency is associated with certain complications including infection, obstruction, and repeated re…
Sponsor: Assiut University • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Your genes could hold the key to better depression treatment
Diagnosis Not yet recruitingBackground: The clinical management of major depressive disorder (MDD) is hampered by the lack of objective biomarkers and high inter-individual variability in drug response, with conventional antidepressants achieving only a 50% response rate. Objective and Design: This prospec…
Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine • Aim: Diagnosis
Last updated Aug 02, 2026 00:00 UTC
-
Can a new pill outsmart depression? a trial puts KH607 to the test
Disease control Not yet recruitingThis trial includes a short-term study and a long-term study. The short-term study is a multicenter, randomized, double-Blind, double-Dummy, Parallel-Controlled study with a 6-week duration. The long-term study is a withdrawal follow-up study; participants meeting relapse criteri…
Phase 3 • Sponsor: Chengdu Kanghong Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Could some breast cancer patients skip radiation entirely?
Disease control Recruiting nowThis is a prospective, multicenter, randomized, open-label, phase III non-inferiority trial designed to evaluate whether omission of postoperative radiotherapy is clinically acceptable in patients with low- and intermediate-risk ductal carcinoma in situ (DCIS) following breast-co…
Phase 3 • Sponsor: Fudan University • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Womb transplant trial offers hope for women born without a uterus
Disease control Recruiting nowThis study will examine the feasibility of initiating a uterine transplant program for Absolute Uterine Factor Infertility (AUFI) at Brigham and Women's Hospital. The investigators plan to screen 30 patients with a goal of enrolling 10 patients. (5 donors and 5 recipients) After …
Phase 2/3 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Targeted radiation plus hormone therapy may slow Low-Volume prostate cancer spread
Disease control Not yet recruitingThis phase II trial tests leuprolide acetate alone versus in combination with 177Lu-PSMA-617, with or without abiraterone acetate and prednisone, for the treatment of hormone-sensitive prostate cancer has spread to a limited number of anatomic sites at the time of initial diagnos…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take aim at autoimmune diseases
Disease control Not yet recruitingThis is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard therapy
Phase 1 • Sponsor: The Affiliated Hospital of Qingdao University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Triple-Drug attack aims to stop liver cancer recurrence after surgery
Disease control Not yet recruitingThis study is conducted to evaluate the efficacy and safety of SHR-8068 combined with Adebrelimab and Apatinib compared with Adebrelimab combined with Apatinib in perioperative treatment of resectable hepatocellular carcinoma with intermediate or high recurrence risk.
Phase 2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Immunotherapy boosts chemo against tough childhood cancer
Disease control Not yet recruitingThis clinical trial investigates the safety, side effects, and effectiveness of combining an immunotherapy drug called dinutuximab-beta with standard induction chemotherapy for patients newly diagnosed with high-risk neuroblastoma. Dinutuximab-beta is an antibody designed to targ…
Phase 1 • Sponsor: Chang Gung Memorial Hospital • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Experimental brain cancer therapy targets tumors directly
Disease control Not yet recruitingThis is a Phase II trial to evaluate the safety, tolerability, efficacy, and PK/ pharmacodynamic profiles of MT027 injected via ICV in participants with recurrent or progressive IDH-wildtype glioblastoma (WHO 2021 CNS Grade 4), who have previously received standard of care (SOC) …
Phase 2 • Sponsor: T-MAXIMUM Pharmaceutical Inc • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Can a Triple-Drug combo shrink Hard-to-Treat colorectal tumors before surgery?
Disease control Recruiting nowThis is a single-arm, multicenter, phase II clinical trial evaluating the safety and efficacy of neoadjuvant encorafenib plus cetuximab N01 and mFOLFOX6 in patients with locally advanced BRAF V600E-mutated colorectal cancer, with or without resectable metastases. Eligible patient…
Phase 2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Could MDMA help veterans heal from PTSD? new study investigates
Symptom relief Recruiting nowA Phase 2, single-center, fixed-dose, open-label study will explore the efficacy, safety, and tolerability of a 120 mg dose of oral MDMA followed by a supplemental dose of 60 mg MDMA in conjunction with therapy in individual versus group settings for adult veterans diagnosed with…
Phase 2 • Sponsor: Sunstone Medical • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
New drug cocktail aims to deepen remission in multiple myeloma patients
Disease control Not yet recruitingThis is an open-label, randomized interventional multicenter Phase 3 clinical trial to investigate the efficacy and safety of Tec-DRd induction therapy and fixed-duration Tec-D maintenance post ASCT in adult participants with TE NDMM, compared with the SoC PERSEUS regimen. A tot…
Phase 3 • Sponsor: University of Heidelberg Medical Center • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Experimental CAR-T therapy takes on tough lupus cases
Disease control CancelledThe purpose of this study is to evaluate the safety and tolerability of P-CD19CD20-ALLO1 in participants with highly active, severe, refractory SLE with or without lupus nephritis (LN). This study includes a dose-escalation stage followed by an expansion stage. It will also evalu…
Phase 1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New Immune-Targeting drug could boost stomach cancer treatment
Disease control Recruiting nowClaudin 18.2 or CLDN18.2 is a protein found on cells in the digestive system. It is also found in some tumors. Researchers are looking at ways to attack CLDN18.2 to help control tumors. ASP2138 is thought to bind to CLDN18.2 and a type of immune cell called a T cell. This "tells"…
Phase 3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Short-Course radiation may boost immunotherapy and chemo for stomach cancer
Disease control Not yet recruitingThis study is a prospective, open-label, multicenter, randomized controlled clinical trial designed to enroll patients with previously untreated, resectable locally advanced adenocarcinoma of the upper stomach or gastroesophageal junction. After providing informed consent and mee…
Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC